Adding Cognitive Remediation Program to Methylphenidate Treatment for Adults with ADHD and Addiction
Improving Short- and Medium-Term Therapeutic Response
Led by Nantes University Hospital · Updated on 2026-02-19
248
Participants Needed
6
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with ADHD who also have addictive disorders to see if adding a cognitive remediation program to methylphenidate treatment improves their symptoms and daily functioning. This study focuses on addressing neuropsychological difficulties common in ADHD with addiction, aiming to provide lasting benefits beyond standard medication and psychosocial care.
Participants will be randomly assigned to one of two programs alongside methylphenidate treatment. The experimental group will use the PRESCO software, which offers cognitive exercises targeting attention, memory, and other related functions through 30 to 45-minute computer sessions twice weekly over 16 weeks. Initially, sessions will be both in-person and at home, with neuropsychologist support and progress tracking. The control group will use AUDITICO software, focusing on auditory stimulation without targeting cognitive deficits, providing a comparable but distinct training experience.
During the study, participants will undergo assessments at the end of the cognitive remediation program and six months later to measure changes in ADHD symptoms, neuropsychological function, addiction severity, and treatment adherence. Researchers will track immediate and sustained improvements using clinical interviews and software data. The total participation duration includes the 16-week treatment period and follow-up evaluations to understand both short- and medium-term effects.
CONDITIONS
Brief Title
MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response
Research Team
C
Clémence Dr Cabelguen, MD-Phd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of ADHD by DIVA-5 interview after specialized ADHD-addiction consultation
Indication for methylphenidate treatment according to European guidelines without contraindications, especially cardiac
Presence of at least one comorbid addictive disorder (substance use disorder and/or behavioral addiction)
Provided consent to participate
Affiliated with the French social security system or equivalent
You will not qualify if you...
Disorders affecting higher functions or inability to read/write French making data collection impossible
Pregnant or breastfeeding women
Persons deprived of liberty
Persons under compulsory psychiatric care
Participation in another interventional research protocol that could affect clinical outcomes
Under guardianship or judicial protection
Consumption of psychoactive substances within 12 hours before a visit
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 16 weeks
Participants undergo a 16-week program involving cognitive exercises using specialized software while receiving methylphenidate treatment. Sessions include computer-based training twice a week, with one session per week conducted with a neuropsychologist during the first 4 weeks and every other week thereafter, and additional sessions completed at home using provided apps.
Twice-weekly sessions, including weekly or biweekly in-person sessions with a neuropsychologist and additional home sessions
Follow-up
Duration - 6 months
Participants are monitored for sustained improvements in ADHD symptoms, neuropsychological function, comorbid addictive disorders, and adherence to methylphenidate treatment for 6 months after completing the cognitive remediation program.
Periodic follow-up visits as scheduled by the study team
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomised controlled trial on the efficacy of adding cognitive remediation therapy to methylphenidate in adult patients with attention deficit hyperactivity disorder and addictive disorders (META): CRT in ADHD and addiction - META study protocol.